Home › Research › Lewy body dementia
The possible role of cerebrolysin in the management of vascular dementia: Leveraging concepts
Hayder Mutter Al-Kuraishy, Ali Ismail Al-Gareeb, Salwa H Zekry, Mubarak Alruwaili, Athanasios T. Alexiou, Marios Papadakis, Gaber El‐Saber Batiha. Neuroscience, 2025-01-18
Topic: Risk, prevention and care in population studies
Plain-language summary
Cerebrolysin (CBL) is a combination of neurotrophic peptides and amino acids derived from pig brains. CBL can cross the blood-brain barrier (BBB) and its biological effect is similar to the effect of endogenous neurotrophic effects. The mechanism of action of CBL is related to the induction of neurogenesis, neuroplasticity, neuroprotection, and neurotrophicity. Therefore, CBL may be effective against the development and progression of neurodegenerative diseases such as Alzheimer disease (AD) and cerebrovascular disorders such as vascular dementia (VD). Moreover, many studies highlighted that CBL is effective in the improvement of cognitive impairment in patients with neurodegenerative diseases. However, the underlying neuroprotective effects of CBL against the VD neuropathology were not fully elucidated. Thus, this review aims to discuss the possible therapeutic efficacy of CBL in the management of VD. In conclusion, CBL could be effective therapeutic strategy in preventing and treating VD by targeting neuroinflammation, BBB injury, and chronic cerebral hypoperfusion.
What this study adds
Evidence grade: Low
This review suggests Cerebrolysin could be an effective strategy in preventing and treating vascular dementia by targeting neuroinflammation, blood-brain barrier injury, and chronic cerebral hypoperfusion. However, the underlying neuroprotective effects of Cerebrolysin against vascular dementia neuropathology were not fully elucidated.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Al-Kuraishy, H. M., Al-Gareeb, A. I., Zekry, S. H., Alruwaili, M., Alexiou, A. T., Papadakis, M., et al. (2025). The possible role of cerebrolysin in the management of vascular dementia: Leveraging concepts. Neuroscience. https://doi.org/10.1016/j.neuroscience.2025.01.040
Vancouver
Al-Kuraishy HM, Al-Gareeb AI, Zekry SH, Alruwaili M, Alexiou AT, Papadakis M, et al. The possible role of cerebrolysin in the management of vascular dementia: Leveraging concepts. Neuroscience. 2025. doi:10.1016/j.neuroscience.2025.01.040. PMID: 39832667.
BibTeX
@article{alkuraishy2025-39832667,
author = {Al-Kuraishy, Hayder Mutter and Al-Gareeb, Ali Ismail and Zekry, Salwa H and Alruwaili, Mubarak and Alexiou, Athanasios T. and Papadakis, Marios and Batiha, Gaber El‐Saber},
title = {{The possible role of cerebrolysin in the management of vascular dementia: Leveraging concepts}},
journal = {Neuroscience},
year = {2025},
doi = {10.1016/j.neuroscience.2025.01.040},
pmid = {39832667},
url = {https://doi.org/10.1016/j.neuroscience.2025.01.040}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- In conclusion, CBL could be effective therapeutic strategy in preventing and treating VD by targeting neuroinflammation, BBB injury, and chronic cerebral hypoperfusion.
Why it matters
This review suggests Cerebrolysin could be an effective strategy in preventing and treating vascular dementia by targeting neuroinflammation, blood-brain barrier injury, and chronic cerebral hypoperfusion. However, the underlying neuroprotective effects of Cerebrolysin against vascular dementia neuropathology were not fully elucidated.
Study details
- Evidence strengthLow
How this study scored 44/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Neuroscience) |
| Journal's citation record | 3 / 4 | Neuroscience: journal h-index 370 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 23 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 7.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 7.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 2 / 4 | Cited 23 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Gaber El‐Saber Batiha: h-index 72 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Witten/Herdecke University: institution h-index 335 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 7 institution(s) in 5 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 39832667) |
| Free to read | 2 / 2 | Free to read |
| Total | 44 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/j.neuroscience.2025.01.040
- PubMed: 39832667
- Original source →
- Free full text: Neuroscience →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Lewy body dementia from nearby years
Also tagged “small”
900 studies in the library carry the topic tag “small”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 900 tagged studies.